Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

Introduction: In this review article the safety and efficacy of of Lifitegrast™ in the management of dry eye disease is described. Methods: Search was carried out using related search terms in data bases like pubmed and related articles were referred. Result: A larger reduction in Eye dryness Score (EDS) was seen with Lifitegrast™. Conclusion: Lifitegrast™ ophthalmic solution 5% provides a new option for the treatment of dry eyes.

Download Full-text

Safety and efficacy of ALG-1007 topical ophthalmic solution – A synthetic peptide that regulates inflammation, in patients with dry eye disease: An exploratory Phase I, open-label, single-center clinical study

American Journal of Ophthalmic Clinical Trials ◽

10.25259/ajoct_1_2020 ◽

2020 ◽

Vol 3 ◽

pp. 10

Author(s):

Richard Lindstrom ◽

Eric Donnenfeld ◽

Edward Holland ◽

Vicken Karageozian ◽

John Park ◽

...

Keyword(s):

Phase I ◽

Dry Eye ◽

Ophthalmic Solution ◽

Dry Eye Disease ◽

Eye Disease ◽

Multiple Time ◽

Open Label ◽

Safety And Efficacy ◽

Treatment Groups ◽

Staining Score

Objectives: The objective of the study was to evaluate the safety and efficacy of ALG-1007 topical ophthalmic solution in patients with dry eye disease (DED). Materials and Methods: This Phase I, prospective, open-label, 12-week study enrolled subjects ≥18 years old with symptoms of DED for at least 6 months and at least one of the following: Total ocular staining score ≥2 or tear film breakup time (TBUT) ≤7 s. Subjects were randomized to four treatment arms: 0.125%, 0.25%, 0.4%, and 0.6% ALG-1007. Subjects received the test drug, 1 drop twice daily, and were followed at multiple time points for 12 weeks. SICCA total ocular staining score, corneal and conjunctival staining score, TBUT, and subject-reported symptoms using the visual analog scale (VAS) symptom index were assessed at baseline and at every visit. The primary safety outcome was percentage and severity of adverse events (AEs). Results: Forty eyes (21 patients) were assigned randomly to four treatment groups (n = 10 per group). Improvement in TBUT, SICCA, and VAS was seen in all groups. The highest dose tested (0.6%) was compared to the lowest dose tested (0.125%) based on change from baseline for all assessments using analysis of variance. Improvement was significantly greater in 0.6% treatment group in terms of TBUT, conjunctiva staining, SICCA, burning, discomfort, photophobia, and the composite symptom score. No serious AEs were reported after 12 weeks of treatment. Conclusion: Outcome measures improved in all the treatment groups. At the highest dose, ALG-1007 demonstrated statistically significant improvement compared to the lowest dose in 7 out of 12 assessments, indicating a dose response. This suggests that the active pharmaceutical ingredient in ALG-1007 is effective in improving signs and symptoms of DED. ALG-1007 was well-tolerated with minimal instillation discomfort and no reported serious AEs.

Download Full-text